Kidney Cancer Today COE

Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges

Details
Laurence Albiges joins Pedro Barata highlighting the phase 2 KEYNOTE-B61 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). This is an area of unmet need and during the ESMO 2022 meeting, Dr. Albiges presented study data for the first time. KEYNOTE-B61 enroll patients with non-clear cell histology that have never been pre...

The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic

Details
Medical Oncologist and member of the scientific committee of the upcoming European International Kidney Cancer Symposium, Samra Turajlic joins Rana McKay to discuss the upcoming IKCS meeting being held April 22nd through the 24th in Antwerpen, Belgium. The program will consist of Award Lectures in Urology and Oncology, Basic Science in renal cell carcinoma (RCC), Biomarkers in RCC, Diagnostics, an...

Overcoming Misinformation in the Diagnosis and Treatment of Kidney Cancer for Patients and Caregivers - Dena Battle

Details
Dena Battle from KCCure, a kidney cancer patient advocacy organization, joins Jaime Landman and Monty Pal to dispel common myths regarding the diagnosis and treatment of kidney cancer being observed in patient communities and to speak about what is driving this misinformation. Among the factors are evolving data, practice-changing data since first diagnoses, the lack of consensus where there isn’t...

Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano

Details
There is a need for more realistic surgical training and the need to train outside of the patient for fellows and residents. The traditional approach of on-patient training is evolving to a great reliance on simulators with more complex platforms. The best patient outcomes from minimally invasive partial nephrectomy, for incidental renal masses, done through either laparoscopy or the robotic platf...

The PDIGREE Trial - Define Rational Sequencing in Combination Treatment of mRCC - Tian Zhang

Details
Principal investigator Tian Zhang joins Alicia Morgans to discuss the recent progress of the currently enrolling PDIGREE (Alliance A031704) trial. PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704) has been open since May of 2019 and now has nearly 300 patients enrolled, many of whom...

Effect of 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial Nephrectomy on Surgical Outcomes - Ketan Badani

Details
Robotic Surgeon Ketan Badani, MD, joins Jaime Landman, MD, and Monty Pal, MD, to discuss the paper, “The Effect of 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial Nephrectomy on Surgical Outcomes” for Kidney Cancer today. Dr. Badani describes the outcomes of this clinical trial, which randomized patients receiving partial nephrectomy to the usual preoperative...

PDIGREE: An adaptive phase III trial of PD-inhibitor Nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI Cabozantinib (CABO) in Metastatic Untreated RCC (Alliance A031704). -Tian Zhang

Details
PDIGREE is a novel adaptive frontline immunotherapy study which upon completion will help answer many important questions regarding treatment duration, when to combine VEGF therapy with IO therapy, and which patients benefit most from IO-VEGF combination upfront vs. sequential therapy. This trial is actively enrolling patients at all National Clinical Trials Network (NCTN) study sites. The primary...

Kidney Cancer Patient Survey Findings: Impacts from the COVID-19 Pandemic - Dena Battle

Details
Recorded Date: March 27, 2020 Jaime Landman and Monty Pal moderate this discussion featuring Dena Battle and Michael Staehler. "In the wake of the COVID-19 outbreak, governments and hospital systems are struggling to determine how to continue to provide care when resources are seriously compromised. Dena Battle, president of KCCure ran a patient survey from March 22 to March 25, asking patients to...

Superfluous Hospital Expenditure Associated with Unnecessary Renal Cyst Surveillance - Lee Ponsky & Laura Bukavina

Details
In this episode of Kidney Cancer Today, Monty Pal and Jamie Landman team up with Laura Bukavina and Lee Ponsky to discuss consults for benign renal cysts undergoing unnecessary active surveillance. Among other topics, their conversation especially touches on present flaws in the healthcare system, including the appropriate evaluation of renal cysts and healthcare disparities in accessibility to ac...

The Use of Active Surveillance in Metastatic Kidney Disease - Jaime Landman and Monty Pal

Details
In this episode of Kidney Cancer Today, Jaime Landman helps Monty Pal dissect some of the biggest issues on active surveillance for renal cell carcinoma. The following questions were discussed. Who is the right patient for active surveillance? Can a T1b patient be a candidate for active surveillance? What are the best clinical practices post five years after resection in the surveillance setting?...
email news signup